A5076270634- CAR-T cell therapy research
- Biosimilars and Bioanalytical Methods
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Integrated Circuits and Semiconductor Failure Analysis
- Complement system in diseases
- Transplantation: Methods and Outcomes
- Advancements in Semiconductor Devices and Circuit Design
- Viral Infectious Diseases and Gene Expression in Insects
- Hematopoietic Stem Cell Transplantation
- Silicon Carbide Semiconductor Technologies
- Nanowire Synthesis and Applications
- Hemoglobinopathies and Related Disorders
- Erythropoietin and Anemia Treatment
- Immune Cell Function and Interaction
- Multiple Myeloma Research and Treatments
- Virus-based gene therapy research
- Renal Transplantation Outcomes and Treatments
- Mesenchymal stem cell research
- Epigenetics and DNA Methylation
- Medical Imaging and Pathology Studies
- Melanoma and MAPK Pathways
- Vector-borne infectious diseases
- Inflammatory Myopathies and Dermatomyositis
- Amyloidosis: Diagnosis, Treatment, Outcomes
Memorial Sloan Kettering Cancer Center
2024-2025
King Faisal Specialist Hospital & Research Centre
2025
New York Hospital Queens
2022-2024
Cornell University
2021-2024
Weill Cornell Medicine
2021-2024
Presbyterian Hospital
2022-2024
NewYork–Presbyterian Hospital
2022-2024
University Hospitals of Cleveland
2021
Abstract Autologous T cells engineered to express a chimeric antigen receptor (CAR) specific for CD19 are approved the treatment of various + hematological malignancies. While CAR induce objective responses in majority patients, relapse frequently occurs upon loss expression by neoplastic cells. Radiation therapy (RT) has been successfully employed circumvent targets preclinical models pancreatic cancer. At least part, this reflects ability RT elicit death (DR) malignant cells, enabling at...
<p>Supplementary Figure 3. Kaplan-Meier survival curves for OS and PFS. Comparisons include (A) (B) PFS CD4 <155 !155 CD4+ T cell counts above below the median day 30 metric of 155 cells/μL. P-values are derived from multivariate Cox proportional hazards model stratified by CAR-T product adjusted confounders, including pre-CAR-T age, LDH pre-lymphodepletion, bridging.</p>
<p>Supplementary Figure 5. Gating strategy for the TBNK assay. (A) FSC vs SSC dot plot was used to identify debris, characterized as low and FSC. Non-debris events are subsequent gating. (B) Using a FSC-A FSC-H plot, singlet gate isused include remove doublet events. (C) Singlet in CD45 is set around CD45+ lymphocyte events, by bright CD45. (D) arethen passed through CD3 CD19 CD19+ B cells CD3+ T cells. (E) further identified CD3+CD4+ helper CD3+CD8+ cytotoxic CD4 CD8 plot. (F)...
<div>Abstract<p>Patients treated with chimeric antigen receptor T-cell (CAR-T) therapy are subject to profound immunosuppression. Dynamics of immune reconstitution (IR) and impacts IR on outcomes following infusion across CAR-T products not well understood. In this study, we profiled in 263 patients relapsed/refractory large B-cell lymphoma receiving (axicabtagene ciloleucel 44.9%, lisocabtagene maraleucel 30.4%, tisagenlecleucel 24.7%). Following infusion, remain persistently...
<p>Supplementary Figure 2. Boxplots with superimposed dot plots demonstrate immune subset distributions at clinically significant timepoints, including days 30, 100, 180, and 365 post-CAR-T. Axi-cel in highlighted blue, liso-cel green, tisa-cel red. Subsets shown are (A) CD4+CCR7-45RA+ effector cells, (B) CD4+CCR7+45RA+ naïve (C) CD4+CCR7+45RA- CM (D) CD8+CCR7+45RA+ (E) CD8+CCR7-45RA+ TEMRA (F) CD8+CCR7-45RA- EM (G) CD8+CCR7+45RA- cells. Ranges of 20 to 45, 80 120, 150 210, 300 400...
<p>Supplementary Figure 1. Immune subset trajectories from time of CAR-T (time 0) through one year 365) following with superimposed boxplots at predefined time-points. Subsets include (A) CD3+ T cells, (B) CD3-19+ B (C) CD3-56+16+ NK (D) CD4+ (E) CD4+CCR7-45RA- EM (F) CD4+CCR7-45RA+ effector (G) CD4+CCR7+45RA- CM (H) CD4+CCR7+45RA+ naïve (I) CD8+ (J) CD8+CCR7-45RA- (K) CD8+CCR7-45RA+ TEMRA (L) CD8+CCR7+45RA- and (M) CD8+CCR7+45RA+ cells. Trajectories depicted are estimated using LOESS...
<p>Supplementary Figure 7. Gating strategy for the T regulatory cells assay. (A, B) CD3+CD4+ helper are passed through a CD25 vs CD127 dot plot to identify CD4+CD127-CD25+ cells, and (C) CCR4 CCR4+CD25+ cells. defined as CD4+CD127-CCR4+CD25+ via series of AND gates.</p>
<p>Supplementary Figure 4. Hazard ratios for OS (in blue) and PFS red) derived from (A) unadjusted Cox proportional hazards models, (B) models stratified by CAR-T product, (C) both product adjusted confounders, including pre-CAR-T age, LDH pre- lymphodepletion, bridging. Each landmark time on the X-axis represents at which are landmarked. For instance, hazard corresponding to 35 utilizes day 20 metrics (using latest measurement within pre-specified range of days 10–35). Similarly, 75...
<p>Supplementary Figure 6. Gating strategy for the T cell subsets assay. (A, B) CD3+CD4+ helper cells are passed through a CCR7 vs CD45RA dot plot to identify CD4+CCR7+CD45RA+ naïve cells, CD4+CCR7+CD45RA- central memory (CM) CD4+CCR7-CD45RA- effector (EM) and CD4+CCR7-CD45RA+ cells. (C, D) Similarly, CD3+CD8+ cytotoxic CD8+CCR7+CD45RA+ CD8+CCR7+CD45RA- CM CD8+CCR7-CD45RA- EM CD8+CCR7-CD45RA+ (TEMRA) cells.</p>
ABSTRACT CD19-targeting chimeric antigen receptor T cells (CART19) have demonstrated significant effectiveness in treating relapsed or refractory large B-cell lymphoma (LBCL). However, they often fail to sustain durable remissions more than half of all treated patients. Therefore, there is an urgent need identify approaches enhance CART19 efficacy. Here, we studied the impact low-dose radiation on activity vitro and find that enhances cytotoxicity against LBCL by upregulating death...
A 70-year-old man with a history of hypertension and chronic migraine presented 10 months progressive generalized muscle weakness stiffness. Physical examination revealed wasting except for hypertrophy bilateral shoulder muscles, deltoid biopsy deposition amorphous material. What is your diagnosis?
We present a 62-year-old gentleman with history of Crohn's disease, G6PD deficiency, who presented immune-mediated thrombotic thrombocytopenia purpura (iTTP) one week after the diagnosis COVID-19 infection. He was admitted worsening dyspnea, acute renal failure, and profound marked schistocytosis on peripheral smear. ADAMTS13 level severely deficient. treated oral prednisone, plasma exchange rituximab complete clinical resolution. Given temporal association this recurrent episode iTTP...
High-dose interleukin-2 (HDIL-2) therapy was initially approved by the U.S. Food and Drug Administration for metastatic renal cell carcinoma (mRCC) melanoma. IL-2 is able to promote CD8+ T natural killer (NK) cytotoxicity increase tumoricidal activity of innate immune system. HDIL-2 associated with a wide spectrum immune-related adverse events (irAEs) that can be radiologically identified. toxicity manifest in multiple organ systems, most significantly leading cardiovascular, abdominal,...
Peripheral blood smear (A) demonstrates increased numbers of plasma cells (representative indicated by arrows), (B) polytypic nature cells.
Pulmonary complications constitute a major cause of morbidity and mortality in the post-allogenic hematopoietic stem cell transplantation (alloHSCT) period. Although chest X-ray (CXR) is customarily used for screening, we have computed tomography (CT) scans. To characterize prevalence abnormalities explore their impact on alloHSCT eligibility outcomes post-transplantation, conducted retrospective analysis using real-world data collected at our center adult patients who were evaluated between...